Matches in SemOpenAlex for { <https://semopenalex.org/work/W130193562> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W130193562 endingPage "9" @default.
- W130193562 startingPage "263" @default.
- W130193562 abstract "The aim of this study was to investigate the efficiency of the FOLFOX-4 regimen and to evaluate the pharmacokinetics of oxaliplatin in untreated patients with metastatic colorectal cancer.43 patients were enrolled in the study. Patients received oxaliplatin 85 mg/m(2) as 2-h i.v. infusion, on day 1, and bolus 5-fluorouracil (5FU) 400 mg/m(2) plus leucovorin (LV) 200 mg/m(2) followed by 5FU 600 mg/m(2) as 22-h infusion on day 1 and 2, every 2 weeks. The pharmacokinetics of oxaliplatin evaluated in 4 patients was performed in blood, plasma and ultrafiltered plasma (UFT) by Inductively Coupled Plasma Mass Spectrometry (ICP-MS).The overall response rate and the median time to progression (TTP) were 53.49% and 7.1 months, respectively. Grade 3-4 toxic effects were observed in 11 (25.5%) patients. Grade 3 neuropathy was observed in 13.95% of the cases. In univariate analysis only Eastern Cooperative Oncology Group (ECOG) performance status (PS) was correlated with response. No correlation was found between grade 3-4 adverse events and the patient characteristics. The area under the time-concentration curve (AUC) in UFT was 4.8 + or - 0.72 standard deviation (SD) microg h/ml and the total clearance 30.17 + or - 7.75 l/min. The values for volume of distribution and the maximum concentration were 567 + or - 20 liters and 0.38 + or - 0.17 ug/ml, respectively.FOLFOX-4 was an effective regimen with good tolerability in previously untreated metastatic colorectal cancer patients. The pharmacokinetics of oxaliplatin was triphasic with a short initial distribution phase and a long terminal elimination phase." @default.
- W130193562 created "2016-06-24" @default.
- W130193562 creator A5001751512 @default.
- W130193562 creator A5005717203 @default.
- W130193562 creator A5027897849 @default.
- W130193562 creator A5037684437 @default.
- W130193562 creator A5049444901 @default.
- W130193562 creator A5050223949 @default.
- W130193562 creator A5063385430 @default.
- W130193562 creator A5064374408 @default.
- W130193562 creator A5068090661 @default.
- W130193562 creator A5071618947 @default.
- W130193562 creator A5077374692 @default.
- W130193562 creator A5089758927 @default.
- W130193562 creator A5090216357 @default.
- W130193562 date "2010-07-27" @default.
- W130193562 modified "2023-10-17" @default.
- W130193562 title "Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters." @default.
- W130193562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20658719" @default.
- W130193562 hasPublicationYear "2010" @default.
- W130193562 type Work @default.
- W130193562 sameAs 130193562 @default.
- W130193562 citedByCount "1" @default.
- W130193562 countsByYear W1301935622015 @default.
- W130193562 crossrefType "journal-article" @default.
- W130193562 hasAuthorship W130193562A5001751512 @default.
- W130193562 hasAuthorship W130193562A5005717203 @default.
- W130193562 hasAuthorship W130193562A5027897849 @default.
- W130193562 hasAuthorship W130193562A5037684437 @default.
- W130193562 hasAuthorship W130193562A5049444901 @default.
- W130193562 hasAuthorship W130193562A5050223949 @default.
- W130193562 hasAuthorship W130193562A5063385430 @default.
- W130193562 hasAuthorship W130193562A5064374408 @default.
- W130193562 hasAuthorship W130193562A5068090661 @default.
- W130193562 hasAuthorship W130193562A5071618947 @default.
- W130193562 hasAuthorship W130193562A5077374692 @default.
- W130193562 hasAuthorship W130193562A5089758927 @default.
- W130193562 hasAuthorship W130193562A5090216357 @default.
- W130193562 hasConcept C112705442 @default.
- W130193562 hasConcept C121608353 @default.
- W130193562 hasConcept C126322002 @default.
- W130193562 hasConcept C126894567 @default.
- W130193562 hasConcept C139254425 @default.
- W130193562 hasConcept C197934379 @default.
- W130193562 hasConcept C2776694085 @default.
- W130193562 hasConcept C2778260052 @default.
- W130193562 hasConcept C2778375690 @default.
- W130193562 hasConcept C2780456651 @default.
- W130193562 hasConcept C2780962732 @default.
- W130193562 hasConcept C2781413609 @default.
- W130193562 hasConcept C43376680 @default.
- W130193562 hasConcept C526805850 @default.
- W130193562 hasConcept C71924100 @default.
- W130193562 hasConcept C90924648 @default.
- W130193562 hasConceptScore W130193562C112705442 @default.
- W130193562 hasConceptScore W130193562C121608353 @default.
- W130193562 hasConceptScore W130193562C126322002 @default.
- W130193562 hasConceptScore W130193562C126894567 @default.
- W130193562 hasConceptScore W130193562C139254425 @default.
- W130193562 hasConceptScore W130193562C197934379 @default.
- W130193562 hasConceptScore W130193562C2776694085 @default.
- W130193562 hasConceptScore W130193562C2778260052 @default.
- W130193562 hasConceptScore W130193562C2778375690 @default.
- W130193562 hasConceptScore W130193562C2780456651 @default.
- W130193562 hasConceptScore W130193562C2780962732 @default.
- W130193562 hasConceptScore W130193562C2781413609 @default.
- W130193562 hasConceptScore W130193562C43376680 @default.
- W130193562 hasConceptScore W130193562C526805850 @default.
- W130193562 hasConceptScore W130193562C71924100 @default.
- W130193562 hasConceptScore W130193562C90924648 @default.
- W130193562 hasIssue "2" @default.
- W130193562 hasLocation W1301935621 @default.
- W130193562 hasOpenAccess W130193562 @default.
- W130193562 hasPrimaryLocation W1301935621 @default.
- W130193562 hasVolume "15" @default.
- W130193562 isParatext "false" @default.
- W130193562 isRetracted "false" @default.
- W130193562 magId "130193562" @default.
- W130193562 workType "article" @default.